The short version
KPV is a tiny three-amino-acid peptide — Lysine-Proline-Valine — derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Your body produces alpha-MSH naturally as part of its inflammatory control system. KPV is the active anti-inflammatory fragment, and research has shown it can calm inflammation through several pathways without the broader hormonal effects of the full alpha-MSH molecule. It is one of the simpler and more targeted anti-inflammatory research peptides available.
How it works — in plain English
KPV works primarily by blocking NF-κB, the master switch that turns on inflammatory gene expression in cells. When NF-κB is activated, it triggers a cascade of pro-inflammatory signals — cytokines like TNF-α and IL-6 that drive tissue inflammation. KPV interrupts this process at the cellular level. In gut research, it enters intestinal cells via a specific transporter (PepT1) that is upregulated during inflammation, meaning it effectively targets the tissue that needs it most when it is most inflamed. It also shows antimicrobial properties in cell studies.
What the research actually shows
- Cell studies consistently show KPV reducing pro-inflammatory cytokine production (TNF-α, IL-6) in stimulated immune and gut cells.
- Animal models of inflammatory bowel disease have shown meaningful reductions in intestinal inflammation following KPV treatment — described as significant anti-inflammatory effects in two separate colitis models.
- Antimicrobial effects have been demonstrated in vitro — including against fungal infections in immune-compromised cell models.
- Human clinical data is limited. KPV has not been through large-scale randomised controlled trials for any condition.
Areas of research interest
KPV is most studied in the context of gut inflammation (IBD, colitis), skin inflammation, and wound healing — all areas where targeted local anti-inflammatory action is desirable. It is a component of the KLOW blend precisely because of this complementary anti-inflammatory mechanism alongside the tissue-repair actions of BPC-157, TB-500 and GHK-Cu.